Silexion Therapeutics Corp (SLXN)

NCM – Real Time Price. Currency in USD

0.46

-0.58 (-55.88%)

Market open: Aug 12, 2026, 11:39 AM EDT

1.08

+0.04 (4.35%)

Previous after-hours: Aug 11, 2026, 7:59 PM EDT

12.08.2026

Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering

GRAND CAYMAN, Cayman Islands, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the pricing of a public offering of an aggregate of 3,846,161 of the Company's ordinary shares (or ordinary share equivalents) and series E warrants to purchase up to 3,846,161 ordinary at a combined public offering price of $0.65 per share (or per ordinary share equivalent) and accompanying warrants. The series E warrants will have an exercise price of $0.65 per share, will be exercisable immediately upon issuance and will expire five years from the date of issuance. The closing of the offering is expected to occur on or about August 13, 2026, subject to the satisfaction of customary closing conditions.

04.08.2026

Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers

Silexion to present SIL-204 data at leading Cancer Symposium designed to feature the latest science in the field of GI cancers Silexion to present SIL-204 data at leading Cancer Symposium designed to feature the latest science in the field of GI cancers

Videos

No Data

There is no data to display

Press releases

12.08.2026

Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering

04.08.2026

Silexion Therapeutics Corp (SLXN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Silexion Therapeutics Corp (SLXN)

Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering

Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers

Videos

No Data

Press releases

Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering

Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers

Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering

Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers

Videos

No Data

Press releases

Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering

Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers

Search stocks

Silexion Therapeutics Corp (SLXN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Silexion Therapeutics Corp (SLXN)

Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering

Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers

Videos

No Data

Press releases

Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering

Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers

Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering

Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers

Videos

No Data

Press releases

Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering

Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers